Overview

This trial is active, not recruiting.

Conditions thyroid cancer, breast cancer
Sponsor Marmara University
Start date February 2011
End date April 2013
Trial size 100 participants
Trial identifier NCT01811199, 09.2011.0024

Summary

Hypothesis: Dexamethasone reduces postoperative emesis in thyroidectomy and mastectomy patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective

Primary Outcomes

Measure
Number of participants will be evaluated to show effect of dexamethasone in reducing postoperative emesis
time frame: up to 3 days

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - breast and thyroid cancer patients no neoadjuvant treated no NSAID or steroid usage heallthy volunteers, signed the informed consent Exclusion Criteria: - ones who did not sign the consent form NSAID or steroid users

Additional Information

Official title Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels
Principal investigator A.Ozdemir Aktan, MD,prof
Description This study has been done to further study the effectiveness of dexamethasone in the prevention of postoperative emesis after breast and thyroid surgery and at the same time, the mechanism of action was investigated. In this prospective, randomized controlled trial it was hypothesized that corticosteroids exert their antiemetic effects in postoperative period via plasma prostaglandin F2 alpha (PGF2 α) and plasma leukotriene C4 (LTC4) inhibition.
Trial information was received from ClinicalTrials.gov and was last updated in March 2013.
Information provided to ClinicalTrials.gov by Marmara University.